IDIOPATHIC PULMONARY FIBROSIS

This study tests an experimental drug called HEC585 in 270 adults with idiopathic pulmonary fibrosis (IPF), a serious lung disease. Participants receive either HEC585, a placebo, or an active comparator (pirfenidone) to see if the drug improves lung function over 24 weeks. The go…

This early-stage study tests whether atezolizumab, a drug used for cancer, is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring. About 24 adults aged 50 and older with confirmed IPF will receive the drug. Researchers will track side eff…

This study tests an experimental drug called ENV-101 in 213 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The goal is to see if ENV-101 can improve lung function and slow disease progression compared to a placebo. Partic…

This study tests a drug called axatilimab in 145 people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The goal is to see if axatilimab can slow the decline in lung function over 26 weeks compared to a placebo. Participants rece…

This study tests a new drug called LYT-100 in 240 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing harder. The goal is to see if LYT-100 can slow the decline in lung function better than an existing drug (pirfenidone) or a placeb…

This study tests an experimental drug called BMS-986278 in people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing harder over time. About 1,255 adults aged 40 and older with IPF will take either the drug or a placebo to see if it slows…

This study is for people with lung scarring (idiopathic pulmonary fibrosis or progressive pulmonary fibrosis) who have already been in a related study. It tests the long-term safety of an inhaled medication called treprostinil. The goal is to see if the drug is safe and tolerable…

This phase 2 trial tests whether the investigational drug CAL101 can slow the loss of lung function in adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. About 150 participants will receive either CAL101 or a placebo by IV infusion once a month for 6…

This study at Duke University is testing whether a special type of MRI (using xenon gas) can track changes in the lungs of people with interstitial lung disease (ILD) who are starting anti-fibrotic therapy. About 60 adults with progressive lung scarring will have MRI scans before…

This study looks at whether a molecule called miR200 in the blood can help identify early-stage idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. Researchers will compare blood samples from 450 people, including those with IPF, other lung diseases, and healthy…

This study looks at whether a special MRI scan using inhaled xenon gas can show changes in lung function for people with idiopathic pulmonary fibrosis (IPF) who are starting approved treatments. About 34 adults with IPF will have the scan before starting therapy and again at 3, 6…